Dataset Information


PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.

ABSTRACT: Although adoptive T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, its success in combating solid tumours has been limited. Here, we report that PTPN2 deletion in T cells enhances cancer immunosurveillance and the efficacy of adoptively transferred tumour-specific T cells. T-cell-specific PTPN2 deficiency prevented tumours forming in aged mice heterozygous for the tumour suppressor p53. Adoptive transfer of PTPN2-deficient CD8+ T cells markedly repressed tumour formation in mice bearing mammary tumours. Moreover, PTPN2 deletion in T cells expressing a chimeric antigen receptor (CAR) specific for the oncoprotein HER-2 increased the activation of the Src family kinase LCK and cytokine-induced STAT-5 signalling, thereby enhancing both CAR T-cell activation and homing to CXCL9/10-expressing tumours to eradicate HER-2+ mammary tumours in vivo. Our findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.


PROVIDER: S-EPMC6960448 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-04-23 | S-SCDT-EMBOJ-2019-103637 | BioStudies
2020-10-03 | E-MTAB-9629 | ArrayExpress
1000-01-01 | S-EPMC5696728 | BioStudies
2019-01-01 | S-EPMC6571101 | BioStudies
2019-01-01 | S-EPMC6325111 | BioStudies
2017-01-01 | S-EPMC5924693 | BioStudies
2021-07-14 | BIOMD0000001014 | BioModels
2021-07-23 | BIOMD0000001013 | BioModels
2020-01-01 | S-EPMC7014796 | BioStudies
2019-01-01 | S-EPMC6889154 | BioStudies